ENLIVEN THERAPEUTICS, INC. Debt Securities, Available-for-sale, Unrealized Loss Position
ENLIVEN THERAPEUTICS, INC. (ELVN) had Debt Securities, Available-for-sale, Unrealized Loss Position of $0 as of 2020-12-31, per its 10-K filed 2022-03-15.
Discontinued › Notes › Debt Securities, Available-for-Sale, Unrealized Loss Position
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition · last filed 2022-03-15
- 2020-12-31: Debt Securities, Available-for-sale, Unrealized Loss Position $0.00.
- 2020-09-30: Debt Securities, Available-for-sale, Unrealized Loss Position $0.00.
- 2019-12-31: Debt Securities, Available-for-sale, Unrealized Loss Position $0.00.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss Position |
|---|---|
| 2020-12-31 | $0.00 10-K · filed 2022-03-15 |
| 2020-09-30 | $0.00 10-Q · filed 2020-11-05 |
| 2019-12-31 | $0.00 10-K · filed 2021-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |